Utilization of hysterectomy following chemoradiation for IB2/IIA2 cervical cancer in the national cancer data base

Research output: Contribution to journalArticlepeer-review

10 Scopus citations


Background/Aim: Performing hysterectomy following chemoradiotherapy (CRT) for IB2/IIA2 cervical cancer is highly controversial. This study evaluated national practice patterns in utilization of post-CRT hysterectomy in the United States compared to CRT alone, as well as outcomes. Materials and Methods: The National Cancer Database was queried for patients with newly diagnosed IB2/IIA2 cervical cancer. Multivariable logistic regression analysis assessing factors predictive of undergoing post-CRT hysterectomy. Kaplan–Meier analysis evaluated overall survival (OS) and Cox proportional hazards modeling determined variables associated with OS. Results: Altogether, 1,691 patients met the inclusion criteria; 1,551 (92%) received CRT alone, and 140 (8%) underwent subsequent hysterectomy. Patients with tumors ≥8 cm were more likely to undergo hysterectomy. Patients who underwent additional hysterectomy, likely a higher-risk cohort, displayed OS comparable to those receiving CRT alone. Conclusion: Greater tumor size was associated with hysterectomy following CRT for IB2/IIA2 cervical cancer in the United States. These patients achieve OS comparable to those receiving standard-of-care CRT.

Original languageEnglish (US)
Pages (from-to)3175-3179
Number of pages5
JournalAnticancer Research
Issue number5
StatePublished - May 2018


  • Cervical cancer
  • Chemotherapy
  • Hysterectomy
  • Radiation therapy
  • United States
  • Humans
  • Middle Aged
  • Kaplan-Meier Estimate
  • Proportional Hazards Models
  • Uterine Cervical Neoplasms/drug therapy
  • Combined Modality Therapy/methods
  • Adult
  • Female
  • Hysterectomy/statistics & numerical data
  • Aged

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Utilization of hysterectomy following chemoradiation for IB2/IIA2 cervical cancer in the national cancer data base'. Together they form a unique fingerprint.

Cite this